Ventricular Tachycardia in Patients With Takotsubo Cardiomyopathy: Prevalence, Predictors, and Associated In-Hospital Adverse Events.

Autor: Elkattawy O; Department of Internal Medicine, Rutgers University New Jersey Medical School, Newark, USA., Shacker M; Department of Internal Medicine, Rutgers University New Jersey Medical School, Newark, USA., Alabed S; Department of Internal Medicine, Rutgers University New Jersey Medical School, Newark, USA., Elias D; Department of Internal Medicine, Rutgers University New Jersey Medical School, Newark, USA., Elkattawy S; Department of Cardiology, St. Joseph's University Medical Center, Paterson, USA., Mohamed O; Department of Medicine, Saint Barnabas Medical Center, Livingston, USA., Mansour C; Department of Internal Medicine, Rutgers University New Jersey Medical School, Newark, USA., Hamlet C; Department of Internal Medicine, Rutgers University New Jersey Medical School, Newark, USA., Emara S; Department of Internal Medicine, Rowan University School of Osteopathic Medicine, Stratford, USA., Shamoon F; Department of Cardiology, St. Joseph's University Medical Center, Paterson, USA.
Jazyk: angličtina
Zdroj: Cureus [Cureus] 2024 Apr 06; Vol. 16 (4), pp. e57724. Date of Electronic Publication: 2024 Apr 06 (Print Publication: 2024).
DOI: 10.7759/cureus.57724
Abstrakt: Introduction  The purpose of this study was to determine the prevalence of ventricular tachycardia (VT) among patients admitted with takotsubo cardiomyopathy (TCM) as well as to analyze the predictors of VT and the predictors of mortality among patients admitted with TCM. Methods Data were obtained from the National Inpatient Sample (NIS) database from January 2016 to December 2019. Patients with a primary diagnosis of TCM were selected using ICD-10 code I51.81. Subsequently, the study population was divided into patients who developed VT vs. patients who did not develop this complication. We then used multivariate logistic regression to assess the predictors of VT in our patient cohort as well as the predictors of mortality among patients admitted with TCM. Results  Of 40114 patients with TCM, 1923 developed VT (4.8%) during their hospital stay. Predictors of VT include atrial fibrillation (AF) (adjusted odds ratio (aOR): 1.592; 95% confidence interval (CI): 0.00-1.424; p=0.001), congestive heart failure (aOR: 1.451; 95% CI: 1.307-1.610; p=0.001), coagulopathy (aOR: 1.436; 95% CI: 1.150-1.793; p=0.001), and patients who self-identify in the race category as Other (aOR: 1.427; 95% CI: 1.086-1.875; p=0.011). Female sex was found to be protective against VT (aOR: 0.587; 95% CI: 0.526-0.656; p=0.001). Predictors of mortality among patients admitted with TCM include, among other factors, age (aOR: 1.014; 95% CI: 1.011-1.018; p=0.001), Asian or Pacific Islander race (aOR: 1.533; 95% CI: 1.197-1.964; p=0.001), Black race (aOR: 1.242; 95% CI: 1.062-1.452; p=0.007), VT (aOR: 1.754; 95% CI: 1.505-2.045; p=0.001), and AF (aOR: 1.441; 95% CI: 1.301-1.597; p=0.001). Some comorbidities that were protective against mortality in TCM include tobacco use disorder (aOR: 0.558; 95% CI: 0.255-0.925; p=0.028) and obstructive sleep apnea (aOR: 0.803; 95% CI: 0.651-0.990; p=0.028). The female sex was found to be protective against mortality (aOR: 0.532; 95% CI: 0.480-0.590; p=0.001).  Conclusion  In a large cohort of women admitted with TCM, we found the prevalence of VT to be 4.8%. Predictors of VT included conditions such as AF and congestive heart failure. The female sex was found to be protective against VT and protective against mortality among patients admitted with TCM.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright © 2024, Elkattawy et al.)
Databáze: MEDLINE
Externí odkaz: